Metabolism Disorder TRIZ Cases

Specific isolated bacteria form functional pathways to correct dysbioses and induce short chain fatty acid production.

Porous silicon carriers adsorb poorly soluble drugs to enhance bioavailability, resolving the contradiction between high solubility and large preparation size.

Fermented thermophilic microorganisms regulate mucous membrane immune and metabolism gene clusters in animals.

Acidified whey protein liquid compositions prevent heat-induced gelling during sterilization to ensure long shelf stability.

Replacing animal gelatin with vegetable gum extends storage time while maintaining rapid disintegration for effective blood lipid reduction.

Specific amino acid substitutions in synthetic GH-RH analogs resist enzymatic degradation while maintaining high binding affinity.

KTPAF50 protein segments immune responses via specific cytokine pathways, reducing cancer cell viability while minimizing side effects.

Moricandia arvensis extract resolves the trade-off between glucose control effectiveness and treatment side effects by improving insulin sensitivity.

Soluble recombinant TLR4 proteins sequester endotoxin in the gut lumen to prevent receptor binding.

Replacing loosely bound ions with divalent cations stabilizes insulin against stomach acid for reliable oral absorption.

Naringenin modulates muscle atrophy mRNA signatures, inhibiting skeletal muscle wasting.

A stable injectable solution uses collagen and acidic pH to form a subcutaneous depot for insulin glargine.

Acylated GIPR antagonist peptides combine with GLP-1 agonists to reduce body weight and food intake through synergistic receptor modulation.

Replacing cook-up starch with hydrophobic variants lowers fat content while maintaining sensoric properties.

Acid and salt treatment with freeze drying creates a plasticised superporous hydrogel that avoids brittle dried materials.

Co-polyamino acid solubilizes basal insulin at neutral pH, enabling stable combination with prandial insulins and GLP-1 analogues.

A small-molecule peptide with a Tyr-Phe sequence inhibits liver fat build-up and regulates blood glucose levels.

N-terminal acylation of CGRP peptides extends half-life via albumin binding, reducing vasodilatory side effects while maintaining metabolic benefits.

Genetic variant analysis identifies specific metabolic disorder mechanisms for targeted therapeutic intervention.

Fusing apelin peptides to an Fc domain extends plasma half-life and reduces dosing frequency while preserving APJ receptor binding.

Macroporous microcapsules resist gastric acid to protect probiotic cells, enabling enzyme delivery in the lower gastrointestinal tract.

APJ receptor agonists activate AMPK and PPAR-gamma pathways to enhance insulin sensitivity, avoiding severe side effects of immunosuppressive agents.

3-hydroxy-dibenzo-alpha-pyrone administration reduces body weight gain without compromising health in obese mammals with Type 2 diabetes.

Microcapsules encapsulate liver cells with erythropoietin to address insufficient engraftment and viability during transplantation.

Cylindrical macro-capsules containing therapeutic cells enable rapid systemic insulin distribution through selective barrier permeability.

Cyclohexyl beta-hydroxy alkyl amines activate beta2-adrenergic receptors to promote glucose uptake in skeletal muscle cells.

Administering ostreolysin increases brown adipose tissue energy expenditure to combat obesity and steatohepatitis despite limited natural tissue availability.

Curcuma oil-based self-nanoemulsifying drug delivery systems enhance oral bioavailability of poorly soluble drugs in personalized 3D printed tablets.

Linagliptin formulation replaces reactive croscarmellose sodium with stable excipients to resolve content uniformity versus stability trade-offs.

A weight loss composition combining banaba leaf, apple fruit, and Rhodiola root extracts with zinc and magnesium chelates.

Segmented film formation and hydration stages resolve manufacturing complexity while sustaining blood ketone levels through improved bioavailability.

Adjusting pH between 6.2 and 9.5 stabilizes protein emulsions, preventing aggregation during heat sterilization and tube feeding.

A mixed extract of Cinnamomi twigs and Moutan root bark reduces body weight and lipid levels while avoiding gastrointestinal side effects.

A single domain antibody binds human PCSK9 to prevent LDL receptor degradation.

Proteolytic enzymes degrade synthetase machinery, preventing intestinal triglyceride reformation and forcing fatty acid energy utilization.

Conjugating GLP-1 to a water-soluble polymer extends circulation time, overcoming rapid clearance and short duration of action.

Elevated pro-neurotensin concentrations correlate with enhanced disease risk, enabling early detection before glucose abnormalities appear.

Activated islet proliferating cells expand rapidly in culture media to generate functional insulin-producing cells, bypassing lengthy differentiation protocols.

Receptor-expressing cell lines identify synergistic microbial contaminants below standard thresholds, ensuring peritoneal dialysis solution safety.

Combining berberine with tyrosol resolves insufficient SIRT1 stimulation from resveratrol monotherapy.

Humanized Ab327 antibody targets IL-21 for autoimmune treatment, resolving safety and efficacy trade-offs.

Targeted amino acid substitutions in GIP peptide analogues resist DPP-4 degradation while maintaining high antagonist potency for metabolic disorders.

Lactobacillus plantarum administration overcomes anaerobic culture constraints to boost Oscillospira abundance and treat dysbiosis.

Superoxide dismutase enzymes from Lactococcus lactis neutralize reactive oxygen species to protect gastrointestinal tissue integrity.

Anti-FGFR1 agonist antibodies resolve poor pharmacokinetics by using segmented receptor targeting to treat metabolic diseases.